41 results about "Hiv disease" patented technology

The invention belongs to the technical field of medicines, and particularly relates to pyrrolo [2, 3-d] pyrimidine compounds of aryl fragments and piperidine fragments as well as a preparation method and application of the pyrrolo [2, 3-d] pyrimidine compounds. The pyrrolo [2, 3-d] pyrimidine compound containing the aryl fragment and the piperidine fragment is an HIV-1 reverse transcriptase inhibitor, and the pyrrolo [2, 3-d] pyrimidine compound further comprises pharmaceutical salt, hydrate and solvate of the pyrrolo [2, 3-d] pyrimidine compound, polycrystal or eutectic of the pyrrolo [2, 3-d] pyrimidine compound, and precursors and derivatives with the same biological functions of the pyrrolo [2, 3-d] pyrimidine compound. The invention also relates to a preparation method of the compound and application of a composition containing one or more of the compounds in related medicines for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

A compound of formula I or a stereoisomer, isotopic isomer, tautomer or pharmaceutically acceptable salt thereof: wherein a ligand that binds to Nef protein (NB) is covalently linked to a ligand that binds to E3 ligase cerebron (CB) via a linker (L).

The invention discloses an AIDS (acquired immune deficiency syndrome) short-term amplification prediction and early warning method and device, electronic equipment and a medium, which are used for solving the problem of how to effectively predict the short-term growth trend of AIDS cases in a region and give an early warning in time under the conditions of short data time span and sparse data. Acquiring newly added data and public attention data of the AIDS cases in the preset time window up to the month in the to-be-detected area; wherein the to-be-detected area comprises a plurality of sub-areas; inputting the newly added data of the AIDS cases and the public attention data into a short-term amplification prediction model for binary pre-training based on a unified large model framework and joint parameter fine tuning, and outputting prediction probabilities of reaching the preset AIDS case amplification in the next month of each sub-region through binary prediction; and for each sub-region, when the prediction probability indicates that the number of newly added AIDS cases in the next month of the sub-region meets a preset AIDS case amplification early warning condition, generating an early warning suggestion of the sub-region.

The invention relates to the technical field of biological medicines, in particular to an injection for treating AIDS and a preparation method thereof. The extraction method of the sulfate algae polysaccharide comprises the following steps: mixing seaweed meal, cellulase and water, carrying out enzymolysis, and extracting for 10-12 hours to obtain an extract; filtering, adding magnesium chloride hexahydrate into filtrate, standing for 20-30 minutes, centrifuging, taking supernatant, removing impurities, adding absolute ethyl alcohol until the final concentration is 55-65%, and precipitating polysaccharide; and purifying the precipitated crude polysaccharide, and freeze-drying to obtain the sulfate algae polysaccharide. The purity of the sulfate algae polysaccharide is greater than or equal to 95%, and the sulfate algae polysaccharide is cooperated with lentinan to obtain a safe and stable injection with an excellent treatment effect on AIDS (Acquired Immune Deficiency Syndrome). And a new scheme is provided for treatment of AIDS.

The application discloses a kind of chronic infectious disease digital people health management system construction method, it relates to AIDS nursing management technical field.Based on Triangle model, the management classification and characteristics of HIV patients are determined by latent profile and association rule analysis, and it is embedded into applet using agile development;Based on the basic nursing framework, the commonality and difference of patients in different levels are explored Care needs;Through the preliminary construction of AIDS hierarchical case management program by range review and focus group interview, the final draft is formed by revising and improving through written evaluation and field demonstration, and the well-constructed management program is embedded into a digital human interaction platform based on artificial intelligence.The application protects the privacy of patients, alleviates the shortage of medical human resources, meets the growing health needs of HIV patients, improves patient satisfaction and improves the quality of HIV care services.

The application provides a 4-quinazolinone derivative containing a benzene sulfonamide piperazine ketone and a preparation method and application thereof. The derivative has the structure shown in the following general formula I. The application further relates to a preparation method of a compound containing the structure of formula I and application of the compound as an HIV-1 / HIV-2 capsid protein regulator in preparation of an anti-AIDS drug.

The invention belongs to the technical field of medicines, and particularly relates to a dihydropteridine-6 (5H)-ketone skeleton compound as well as a preparation method and application thereof. The dihydropteridine-6 (5H)-ketone skeleton compound disclosed by the invention is an HIV-1 (Human Immunodeficiency Virus-1) non-nucleoside reverse transcriptase inhibitor; the invention also comprises pharmaceutical salts, hydrates, solvates, polycrystals or co-crystals of the compounds, precursors and derivatives with the same biological functions of the compounds, a preparation method of the compounds and application of a composition containing one or more of the compounds in preparation of related drugs for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

The invention discloses an application of a UFMylation regulator in preparation of a medicine for resisting HIV (Human Immunodeficiency Virus) infection. According to the application disclosed by the invention, through in-vivo and in-vitro pharmacodynamic experiments, the inhibition effect of a UFMylation regulator, namely a UFSP2 inhibitor Compond-8, on an HIV (Human Immunodeficiency Virus) is evaluated. Experimental results show that the Compound 8 can significantly inhibit the replication of MT-4 cells, primary CD4 + T cells and HIV viruses in mice, can still maintain low virus load after drug withdrawal, has no obvious influence on the proliferation of normal cells and the weight of mice, and has a good anti-HIV infection effect and high safety. The invention reveals that the Compound 8 effectively inhibits HIV-1 replication for the first time, prompts that the Compound 8 can be used as a candidate drug of an HIV-1 treatment drug, provides a new treatment strategy for AIDS, and has a wide application prospect in the field of HIV infection resistance.

Provided are a genetically modified immune cell, a preparation method therefor, and an application. The immune cell overexpresses HIL-6 and / or L-GP130. HIL-6 or L-GP130 continuous overexpression / conditionally induced overexpression in the immune cell reduces the side effects of CAR-T therapy while maintaining immune and anti-tumour effects, and has potential value in the treatment of malignant tumours and AIDS.

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)—or the like; each R1 independently represents a halogen atom or the like; each of R1a and R1b independently represents a hydrogen atom or the like, R2represents an alkyl group or a haloalkyl group, R3represents a hydrogen atom or an alkyl group; and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof; and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

Provided in the present invention are novel compounds, a composition thereof, a preparation method therefor and the use thereof. The compounds (I) and the composition thereof of the present invention have a significant anti-human immunodeficiency virus effect, and have significantly improved in-vivo bioavailability.

The present application relates to a kind of multispecific and / or multivalent binding protein for preventing and / or treating HIV infection, it includes at least 3 antigen binding sites, part of antigen binding site is specifically bound HIV-1-gp41 or HIV-1-gp120 or HIV-1-gp160, still part of antigen binding site is specifically bound human CD4 receptor or human CCR5 receptor;The binding protein of the present application has excellent broad-spectrum neutralizing ability in the treatment or prevention of HIV infection, provides a new solution for the problem of drug resistance escape caused by HIV virus variation, in addition, the present application inventor also unexpectedly found that the binding protein of the present application can treat or prevent the tumor-related disease caused by HIV infection.

The application provides a benzene sulfonamide piperazine ketone glycine derivative and a preparation method and application thereof. The derivative has a structure shown in the following general formula I. The application also relates to a preparation method of a compound containing the structure of formula I and application of the compound as an HIV-1 / 2 capsid protein regulator in preparation of an anti-AIDS drug.

Disclosed herein are identified compound fragments, compounds and their pharmaceutically acceptable salts, isotopes or solvates, useful as antiviral drug and / or as a hepatic-targeted drug, such as for the treatment of HBV, HDV and / or HIV.

This invention provides primer sets, probes, kits for expressing interferon-stimulated genes IFI27 and IFI6, and their use in evaluating the immune reconstitution status of HIV-infected individuals.

The application provides a kit for anti-AIDS drug detection and a detection method of anti-AIDS drugs, the kit comprises a sample stable control liquid, a mixed internal standard working liquid, a protein precipitant, a special reconstitution solution, a standard and a quality control; the sample stable control liquid comprises a buffer solution containing sodium fluoride and EDTA-2Na. The kit and the detection method provided by the application realize in-vitro stable control of a very low degradation level of prodrug components, guarantee the authenticity of source data of clinical diagnosis, overcome the technical prejudice that weak ionization components cannot be detected by positive ions, significantly improve the detection flux and the quantitative precision of a narrow treatment window, perfectly balance the physical solvent behavior of 'large polarity span' components, completely eliminate the matrix inhibition at dead volume, and establish the highest standard quantitative mechanism of full isotope matching, have very high anti-interference ability and compliance, and can simultaneously quantitatively detect seven anti-AIDS drugs in biological samples.

The application discloses a proteolysis body (PROTAC) targeting HIV protease and application thereof, the PROTAC is a polypeptide structure, a general formula is R1-L-E3L or R1-L-E3L-R2, wherein R1 is a target ligand of HIV protease, L is a GSGS linker, E3L is a ligand of VHL (von Hippel-Lindau) E3 ubiquitin ligase, and R2 is a D-configuration arginine cell penetration peptide; the PROTAC can recruit E3 ligase, specifically induce ubiquitination and degradation of HIV protease in a proteasome-dependent manner; the application further provides a gene encoding the PROTAC, a recombinant carrier, a pharmaceutical preparation and application of the gene in preparation of an anti-AIDS drug.

The purpose of the present invention is to provide a method for detecting whether a subject is infected with AIDS virus (HIV) or is in a latent HIV infection state, or whether the subject is suspected of being infected with HIV or being in a latent HIV infection state.　The present invention provides a method for determining whether a mammalian subject is infected with HIV or is in a latent HIV infection state, or whether the mammalian subject is suspected of being infected with HIV or being in a latent HIV infection state, the method involving: a step for detecting the amount of 3-methylcytidine (m3C) in a sample derived from the subject; and a step for providing information on the detected amount for the determination.

This invention provides a complement protein composition for assessing the risk of HIV / AIDS and its application, belonging to the field of disease risk assessment technology. The complement protein composition includes C1RL, C4BP, C7-cDNAFLJ78207, C7-cDNAFLJ93143, CFB, and CFHR2. By detecting the expression levels of the above complement protein composition in test serum and healthy human serum, if the expression of C4BP, C7-cDNAFLJ78207, and C7-cDNAFLJ93143 is upregulated, and the expression of C1RL, CFB, and CFHR2 is downregulated, it indicates a high risk of HIV / AIDS. This invention, by detecting the expression levels of each complement protein in the above complement protein composition, can rapidly assess the level of HIV / AIDS risk, providing a new option for HIV / AIDS detection reagents.

The invention relates to the technical field of antibodies, in particular to an LAM polyclonal antibody as well as a preparation method and application thereof. The polyclonal antibody designed by the invention is wide in detection range and is still suitable for non-AIDS patients; the kit can specifically recognize LAM of mycobacteria, including LAM of mycobacterium tuberculosis and LAM of slowly-growing and rapidly-growing nontuberculous mycobacteria (NTM), and can be used for detecting tuberculosis and nontuberculous mycobacterium diseases. The antibody combination provided by the invention has high sensitivity and high specificity, can be used for qualitative and quantitative analysis of LAM antigens in various types of samples (especially body fluid samples), and is helpful for improving the accuracy of detection results.

The present invention relates to a composition comprising an RNA molecule, wherein the RNA molecule comprises an expression cassette encoding an immunogenic peptide, the peptide comprising at least two fragments, each fragment comprising at least one epitope, the epitope being derived from an amino acid sequence encoded by human immunodeficiency virus (HIV), and to a pharmaceutical formulation comprising such a composition. Furthermore, the present invention relates to a method for preventing or treating HIV.

The application discloses application of a PHD3 inhibitor in prevention and treatment of AIDS. Through immunological, biochemical and other multidisciplinary research means, the application analyzes the mechanism that a viral antisense protein ASP inhibits production of type I IFN to realize immune escape and establish latent infection in an HIV-1 infection process. Mechanically, after being expressed into a protein in a cell in the body, the ASP needs to undergo post-translational modification to exert its inhibiting effect, and after hydroxylation modification of a 47-position proline, the ASP can help to realize the ability of inhibiting the body immune response, and the post-translational modification depends on a host proline hydroxylase 3 (PHD3) to realize. Based on the mechanism-based research, it is found that a PHD3 inhibitor Molidustat offsets the hydroxylation of the ASP by PHD3, thereby blocking the immune evasion of HIV-1 and antagonizing infection, and showing a good development prospect of an AIDS treatment and prevention drug.

The application provides an HIV-1 capsid protein degradation agent based on a hydrophobic tag technology and a preparation method and application thereof. The HIV-1 capsid protein degradation agent has the structure shown in general formula I or II. The application further relates to a preparation method of the compound and application of the compound as the HIV-1 capsid protein degradation agent in preparation of an anti-AIDS drug.

The invention provides a traditional Chinese medicine external composition for treating AIDS (acquired immune deficiency syndrome) cutaneous pruritus. The external traditional Chinese medicine composition for treating AIDS cutaneous pruritus is prepared from, by weight, 1 part of radix saposhnikoviae, 1 part of radix cynanchi paniculati, 1 part of radix sophorae flavescentis, 1 part of cortex dictamni, 1 part of radix et rhizoma rhei, 1 part of cortex phellodendri, 1 part of radix scutellariae, 1 part of radix angelicae sinensis, 1 part of radix arnebiae seu lithospermi, 1 part of radix ophiopogonis, 1 part of radix asparagi, 1 part of cortex pseudolaricis, 1 part of fructus cnidii, 1 part of pericarpium zanthoxyli, 1 part of radix astragali, 1 part of radix glycyrrhizae, 1 part of rhizoma bletillae and 1 part of radix ampelopsis. The external traditional Chinese medicine composition for treating AIDS skin itch provided by the invention has the advantages of effectively relieving itch, shortening the disease course, promoting rash fading and improving the immune function.

This invention belongs to the field of pharmaceutical technology, specifically relating to a pyrimidine cyclic compound containing deuterated methyl groups, its preparation method, and its uses. The compound structure of this invention is shown in general formula I, and also includes its pharmaceutical salt, hydrate, and solvate, its polycrystalline or cocrystalline forms, and its precursors and derivatives with similar biological functions. This compound or its composition can be used to prepare drugs for the prevention or treatment of AIDS and related diseases. In vitro cellular level anti-HIV-1 activity experiments show that this type of small molecule has strong anti-HIV-1 biological activity, significantly inhibiting viral replication in HIV-1-infected MT-4 cells, and exhibiting low cytotoxicity.

The present application relates to a kind of V3 neutralizing antibody isolated from SHIV attack rhesus monkey in vivo, it is related to biomedical field.It is specifically related to the monoclonal antibody gene obtained from the specific memory B cell in the rhesus monkey attacked by SHIV, candidate monoclonal antibody is expressed in eukaryotic cell, and the antibody with higher broad-spectrum neutralizing activity is screened by function analysis.The present application is further related to the use of the above-mentioned monkey-derived monoclonal broad-spectrum neutralizing antibody for AIDS vaccine design and HIV-1 infected person treatment and the like.

This invention belongs to the field of pharmaceutical technology, specifically relating to heteroarylpyrimidine derivatives containing a pyridine-benzene ring structure, their preparation methods, and uses. The compounds of this invention are heteroarylpyrimidine derivatives containing a pyridine-benzene ring structure, and also include their pharmaceutical salts, hydrates, and solvates, as well as their polycrystalline or cocrystalline forms, and their precursors and derivatives with similar biological functions. These compounds or combinations thereof can be used to prepare drugs for the prevention or treatment of AIDS and related diseases. In vitro cellular level anti-HIV-1 activity experiments show that these small molecules possess strong anti-HIV-1 biological activity, significantly inhibiting viral replication in HIV-1-infected MT-4 cells, and exhibiting low cytotoxicity.

The application discloses application of a UFMylation regulator in preparation of a medicine for resisting HIV infection. + The application evaluates the inhibiting effect of the UFMylation regulator, namely, the UFSP2 inhibitor Compound-8, on HIV virus through in-vivo and in-vitro pharmacodynamic experiments. The experimental results show that Compound-8 can significantly inhibit the replication of HIV virus in MT-4 cells, primary CD4 T cells and mice, can maintain a low viral load after drug withdrawal, and has no obvious influence on the proliferation of normal cells and the weight of mice, and has good anti-HIV infection effect and high safety. The application firstly discloses that Compound-8 effectively inhibits HIV-1 replication, indicates that Compound-8 can be used as a candidate medicine for HIV-1 treatment medicine, provides a new treatment strategy for AIDS, and has a wide application prospect in the field of anti-HIV infection.

The invention relates to an AIDS antiviral treatment data monitoring method and device and a computer. The method comprises the following steps: acquiring physical state information of an abnormal object, and acquiring treatment role information for the abnormal object; performing federal data sharing on the body state information and the treatment role information to obtain an object sharing information set; performing medical detection data calculation on the object shared information set to obtain an object abnormal index calculation result; and performing multi-source data contrastive analysis on the object abnormal index calculation result to obtain abnormal trend analysis data for the abnormal object. By adopting the method, current complex and changeable treatment situations and ever-increasing patient management requirements can be met.

The application discloses a benzalkonium chloride contraceptive gel for killing AIDS pathogens and a preparation method thereof, and belongs to the technical field of biological medicine manufacturing. The benzalkonium chloride contraceptive gel is prepared from water, hydroxypropyl methyl cellulose, polyquaternium-10, modified cyclodextrin, disodium edetate, benzalkonium chloride and glycerol in a specific proportion. In the preparation, the hydroxypropyl methyl cellulose and the polyquaternium-10 are first dispersed by heating, and then the water solution of the modified cyclodextrin, the disodium edetate and the benzalkonium chloride is sucked into the mixture after cooling, and the glycerol is added, and the finished product is obtained through cooling homogenization and vacuum degassing. Compared with the prior art, the amino acid grafted modified cyclodextrin enhances the inclusion and mucosal adhesion performance, the obtained gel has a fast inactivation rate for the AIDS pathogens, a long vaginal retention time, and has the high-efficiency antiviral and long-acting barrier effects, and has low irritation and is safe and reliable.